Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells

Cancer Letters

Volumn 420, Issue , 2018, Pages 1-13

  Xu, Wei ^a,b   Liu, Hao ^c   Liu, Zhi Gang ^a   Wang, Hong Sheng ^d   Zhang, Fan ^e   Wang, Hao ^f   Zhang, Ji ^b   Chen, Jing Jing ^g   Huang, Hong Jun ^a   Tan, Yuan ^a   Cao, Meng Ting ^b   Du, Jun ^d   Zhang, Qiu Gui ^b   Jiang, Guan Min ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^f ANHUI MEDICAL UNIVERSITY   (China)

^g Sinocare Biosensing Limited Company   (China)

Author keywords

Epithelial mesenchymal transitions; Histone deacetylase inhibitors; Snail stabilization; Transcriptional activation; Tumor metastasis

Indexed keywords

COP9 SIGNALOSOME; HISTONE DEACETYLASE INHIBITOR; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; SNAI1 PROTEIN, HUMAN;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INCUBATION TIME; LIVER CELL CARCINOMA; METASTASIS POTENTIAL; MOLECULAR STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; UBIQUITINATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CANCER TRANSPLANTATION; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; METASTASIS; PHOSPHORYLATION; PROTEIN STABILITY; TUMOR CELL LINE;

ACETYLATION; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COP9 SIGNALOSOME COMPLEX; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN STABILITY; SMAD2 PROTEIN; SMAD3 PROTEIN; SNAIL FAMILY TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 85041606155     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2018.01.068     Document Type: Article

References (50)

1. Zhang, H., Shang, Y.P., Chen, H.Y., Li, J., Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol. Res. Off. J. Jpn. Soc. Hepatol., 2016.
2. Armeanu, S., Pathil, A., Venturelli, S., Mascagni, P., Weiss, T.S., Gottlicher, M., Gregor, M., Lauer, U.M., Bitzer, M., Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J. Hepatol. 42 (2005), 210–217.
3. Rajak, H., Singh, A., Raghuwanshi, K., Kumar, R., Dewangan, P.K., Veerasamy, R., Sharma, P.C., Dixit, A., Mishra, P., A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity. Curr. Med. Chem. 21 (2014), 2642–2664.
4. David, G., Alland, L., Hong, S.H., Wong, C.W., DePinho, R.A., Dejean, A., Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16 (1998), 2549–2556.
5. Li, Q.Q., Hao, J.J., Zhang, Z., Hsu, I., Liu, Y., Tao, Z., Lewi, K., Metwalli, A.R., Agarwal, P.K., Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: a proteomic approach. Int. J. Oncol. 48 (2016), 2591–2607.
6. Huang, H., Reed, C.P., Zhang, J.S., Shridhar, V., Wang, L., Smith, D.I., Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Canc. Res. 59 (1999), 2981–2988.
7. Sambucetti, L.C., Fischer, D.D., Zabludoff, S., Kwon, P.O., Chamberlin, H., Trogani, N., Xu, H., Cohen, D., Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274 (1999), 34940–34947.
8. Jiang, G.M., He, Y.W., Fang, R., Zhang, G., Zeng, J., Yi, Y.M., Zhang, S., Bu, X.Z., Cai, S.H., Du, J., Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels. Int. J. Biochem. Cell Biol. 42 (2010), 1840–1846.
9. Zhang, P., Jiang, G., Gao, J., Li, L., Du, J., Jiao, X., SAHA down-regulates the expression of indoleamine 2,3-dioxygenase via inhibition of the JAK/STAT1 signaling pathway in gallbladder carcinoma cells. Oncol. Rep. 29 (2013), 269–275.
10. Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R., Pazdur, R., FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncol. 12 (2007), 1247–1252.
11. Bailey, H., Stenehjem, D.D., Sharma, S., Panobinostat for the treatment of multiple myeloma: the evidence to date. Hematol. Res. Rev. 6 (2015), 269–276.
12. Zhang, L., Fang, H., Xu, W., Strategies in developing promising histone deacetylase inhibitors. Med. Res. Rev. 30 (2010), 585–602.
13. Ramalingam, S.S., Belani, C.P., Ruel, C., Frankel, P., Gitlitz, B., Koczywas, M., Espinoza-Delgado, I., Gandara, D., Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J. Thorac. Oncol.: Off. Publ. Int. Ass. Study. Lung Canc. 4 (2009), 97–101.
14. Golay, J., Cuppini, L., Leoni, F., Mico, C., Barbui, V., Domenghini, M., Lombardi, L., Neri, A., Barbui, A.M., Salvi, A., Pozzi, P., Porro, G., Pagani, P., Fossati, G., Mascagni, P., Introna, M., Rambaldi, A., The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 21 (2007), 1892–1900.
15. Parbin, S., Kar, S., Shilpi, A., Sengupta, D., Deb, M., Rath, S.K., Patra, S.K., Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J. Histochem. Cytochem. Off. J. Histochem. Soc. 62 (2014), 11–33.
16. Butler, K.V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., Kozikowski, A.P., Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132 (2010), 10842–10846.
17. Manal, M., Chandrasekar, M.J., Gomathi Priya, J., Nanjan, M.J., Inhibitors of histone deacetylase as antitumor agents: a critical review. Bioorg. Chem. 67 (2016), 18–42.
18. Ganslmayer, M., Konturek, P., Herold, C., Neurath, M.F., Zopf, S., Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo. Anticancer Res. 32 (2012), 5263–5269.
19. Coradini, D., Speranza, A., Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol. Sin. 26 (2005), 1025–1033.
20. Wagner, J.M., Hackanson, B., Lubbert, M., Jung, M., Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenet. 1 (2010), 117–136.
21. Debeb, B.G., Lacerda, L., Xu, W., Larson, R., Solley, T., Atkinson, R., Sulman, E.P., Ueno, N.T., Krishnamurthy, S., Reuben, J.M., Buchholz, T.A., Woodward, W.A., Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/beta-catenin signaling. Stem Cells 30 (2012), 2366–2377.
22. Shook, D., Keller, R., Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech. Dev. 120 (2003), 1351–1383.
23. Thiery, J.P., Sleeman, J.P., Complex networks orchestrate epithelial-mesenchymal transitions, Nature reviews. Mol. Cell. Biol. 7 (2006), 131–142.
24. Kokkinos, M.I., Wafai, R., Wong, M.K., Newgreen, D.F., Thompson, E.W., Waltham, M., Vimentin and epithelial-mesenchymal transition in human breast cancer–observations in vitro and in vivo. Cells Tissues Organs 185 (2007), 191–203.
25. Zeisberg, M., Neilson, E.G., Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 119 (2009), 1429–1437.
26. Liu, Z.C., Chen, X.H., Song, H.X., Wang, H.S., Zhang, G., Wang, H., Chen, D.Y., Fang, R., Liu, H., Cai, S.H., Du, J., Snail regulated by PKC/GSK-3beta pathway is crucial for EGF-induced epithelial-mesenchymal transition (EMT) of cancer cells. Cell Tissue Res. 358 (2014), 491–502.
27. Cano, A., Perez-Moreno, M.A., Rodrigo, I., Locascio, A., Blanco, M.J., del Barrio, M.G., Portillo, F., Nieto, M.A., The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2 (2000), 76–83.
28. Zhou, B.P., Deng, J., Xia, W., Xu, J., Li, Y.M., Gunduz, M., Hung, M.C., Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6 (2004), 931–940.
29. Blanco, M.J., Moreno-Bueno, G., Sarrio, D., Locascio, A., Cano, A., Palacios, J., Nieto, M.A., Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 21 (2002), 3241–3246.
30. Moody, S.E., Perez, D., Pan, T.C., Sarkisian, C.J., Portocarrero, C.P., Sterner, C.J., Notorfrancesco, K.L., Cardiff, R.D., Chodosh, L.A., The transcriptional repressor Snail promotes mammary tumor recurrence. Canc. Cell 8 (2005), 197–209.
31. Xue, C., Plieth, D., Venkov, C., Xu, C., Neilson, E.G., The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Canc. Res. 63 (2003), 3386–3394.
32. Behrens, J., Mareel, M.M., Van Roy, F.M., Birchmeier, W., Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J. Cell Biol. 108 (1989), 2435–2447.
33. Yang, S.W., Zhang, Z.G., Hao, Y.X., Zhao, Y.L., Qian, F., Shi, Y., Li, P.A., Liu, C.Y., Yu, P.W., HIF-1alpha induces the epithelial-mesenchymal transition in gastric cancer stem cells through the Snail pathway. Oncotarget 8 (2017), 9535–9545.
34. Thaper, D., Vahid, S., Nip, K.M., Moskalev, I., Shan, X., Frees, S., Roberts, M.E., Ketola, K., Harder, K.W., Gregory-Evans, C., Bishop, J.L., Zoubeidi, A., Targeting Lyn regulates Snail family shuttling and inhibits metastasis. Oncogene 36 (2017), 3964–3975.
35. Suzuki, H., Yagi, K., Kondo, M., Kato, M., Miyazono, K., Miyazawa, K., c-Ski inhibits the TGF-beta signaling pathway through stabilization of inactive Smad complexes on Smad-binding elements. Oncogene 23 (2004), 5068–5076.
36. Wu, Y., Deng, J., Rychahou, P.G., Qiu, S., Evers, B.M., Zhou, B.P., Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Canc. Cell 15 (2009), 416–428.
37. Richardson, K.S., Zundel, W., The emerging role of the COP9 signalosome in cancer. Molecular Canc. Res. MCR 3 (2005), 645–653.
38. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics, CA. Canc. J. Clinic. 61 (2011), 69–90.
39. Llovet, J.M., Burroughs, A., Bruix, J., Hepatocellular carcinoma. Lancet 362 (2003), 1907–1917.
40. Llovet, J.M., Di Bisceglie, A.M., Bruix, J., Kramer, B.S., Lencioni, R., Zhu, A.X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., Gores, G.J., H.C.C.D.C.T, Panel of Experts in, Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl. Cancer Inst. 100 (2008), 698–711.
41. Llovet, J.M., Bruix, J., Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48 (2008), 1312–1327.
42. Byrd, J.C., Marcucci, G., Parthun, M.R., Xiao, J.J., Klisovic, R.B., Moran, M., Lin, T.S., Liu, S., Sklenar, A.R., Davis, M.E., Lucas, D.M., Fischer, B., Shank, R., Tejaswi, S.L., Binkley, P., Wright, J., Chan, K.K., Grever, M.R., A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105 (2005), 959–967.
43. Prince, H.M., Bishton, M.J., Harrison, S.J., Clinical studies of histone deacetylase inhibitors. Clinic. Canc. Res. Off. J. Am. Ass. Canc. Res. 15 (2009), 3958–3969.
44. Reid, T., Valone, F., Lipera, W., Irwin, D., Paroly, W., Natale, R., Sreedharan, S., Keer, H., Lum, B., Scappaticci, F., Bhatnagar, A., Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Canc. 45 (2004), 381–386.
45. Stadler, W.M., Margolin, K., Ferber, S., McCulloch, W., Thompson, J.A., A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Canc. 5 (2006), 57–60.
46. Blumenschein, G.R. Jr., Kies, M.S., Papadimitrakopoulou, V.A., Lu, C., Kumar, A.J., Ricker, J.L., Chiao, J.H., Chen, C., Frankel, S.R., Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest. N. Drugs 26 (2008), 81–87.
47. Yook, J.I., Li, X.Y., Ota, I., Fearon, E.R., Weiss, S.J., Wnt-dependent regulation of the E-cadherin repressor snail. J. Biol. Chem. 280 (2005), 11740–11748.
48. Lachenmayer, A., Toffanin, S., Cabellos, L., Alsinet, C., Hoshida, Y., Villanueva, A., Minguez, B., Tsai, H.W., Ward, S.C., Thung, S., Friedman, S.L., Llovet, J.M., Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J. Hepatol. 56 (2012), 1343–1350.
49. LaBonte, M.J., Wilson, P.M., Fazzone, W., Russell, J., Louie, S.G., El-Khoueiry, A., Lenz, H.J., Ladner, R.D., The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Canc. Res. 71 (2011), 3635–3648.
50. Ellis, L., Pili, R., Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals 3 (2010), 2411–2469.